15-Oct-2026
Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Immutep regains Nasdaq bid-price compliance after 10-day streak above $1 and an ADS ratio change
Market Chameleon (Tue, 13-Oct 7:45 AM ET)
Immutep regains minimum bid price compliance with Nasdaq
Seeking Alpha News (Tue, 13-Oct 8:49 AM ET)
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
Globe Newswire (Tue, 13-Oct 8:00 AM ET)
Immutep Receives ~A$0.86 Million R&D Tax Incentive
Globe Newswire (Wed, 30-Sep 8:00 AM ET)
Change to American Depositary Share Ratio
Globe Newswire (Mon, 21-Sep 8:00 AM ET)
Immutep Outlines Focused Development Strategy for Eftilagimod Alfa ('efti')
Globe Newswire (Fri, 11-Sep 8:00 AM ET)
Immutep Quarterly Activities Report Q4 FY26
Globe Newswire (Thu, 30-Jul 8:00 AM ET)
Globe Newswire (Fri, 24-Jul 8:00 AM ET)
IMMP Faces Securities Investigation After 80-90% Collapse Tied to Halted TACTI-004 Trial
Market Chameleon (Thu, 16-Apr 7:13 AM ET)
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Immutep Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol IMMP.
As of October 15, 2026, IMMP stock price declined to $3.21 with 18,676 million shares trading.
IMMP has a beta of 4.73, meaning it tends to be more sensitive to market movements. IMMP has a correlation of 0.08 to the broad based SPY ETF.
IMMP has a market cap of $23.65 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, IMMP traded as high as $70.60 and as low as $3.06.
The top ETF exchange traded funds that IMMP belongs to (by Net Assets): IBB.
IMMP has underperformed the market in the last year with a price return of -92.4% while the SPY ETF gained +17.2%. IMMP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -63.2% and -29.3%, respectively, while the SPY returned +2.5% and +1.0%, respectively.
IMMP support price is $3.18 and resistance is $3.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMMP shares will trade within this expected range on the day.
